Fri, Oct 24, 2014, 8:01 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

NPS Pharmaceuticals, Inc. Message Board

  • dcaf7 dcaf7 Feb 26, 2013 3:18 PM Flag

    Sensipar news

    WASHINGTON (AP) -- Federal health regulators have halted Amgen's studies of its thyroid drug Sensipar after the death of a 14-year-old patient in a company trial.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The Food and Drug Administration said Tuesday it is still gathering information about the death, but has shut down all studies of the drug in children.

      Sensipar is approved in adults to treat over-activity of the parathyroid gland. It has been used since 2004 to treat symptoms of chronic kidney disease and parathyroid cancer.

      Amgen Inc. had been studying the drug to see whether it works in children.

      The Thousand Oaks, Calif.-based company said in a statement that it "is working as rapidly as possible to understand the circumstances of what happened."

      The FDA said on its website that it is unclear whether Amgen's drug had a role in the patient's death, but it is reminding doctors to prescribe it carefully.

      The drug is known to lower calcium levels, sometimes to a dangerous extent.

      The agency says doctors should monitor patients' calcium levels monthly to make sure they don't fall to dangerous levels. Signs of a calcium deficiency include muscle cramping, convulsions and burning or prickling sensations.

 
NPSP
26.93-2.15(-7.39%)Oct 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.